Search Results
Aug 31, 2026, 09:00 ET EIT Pharma Closes Oversubscribed $35 Million Series A Round, Led by Propel Bio Partners
lonafarnib for the treatment of chronic hepatitis D (CHD), a serious life-threatening liver disease caused by hepatitis D virus (HDV) in individuals who already have hepatitis B virus infection. Lonafarnib is an investigational first-in-class oral CHD therapy candidate with a unique mechanism of action.
More news about: EIT Pharma
Aug 31, 2026, 03:18 ET AMGEN'S REPATHA® REDUCES RISK OF DEATH IN PATIENTS AT HIGH RISK FOR A FIRST HEART ATTACK OR STROKE
England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization
More news about: Amgen
Aug 19, 2026, 08:30 ET Renata Medical Closes $25M Series D Financing Led by Global Healthcare Investment Firm ARCHIMED to Accelerate Commercialization and Development of Pediatric Cardiovascular Technologies
/PRNewswire/ -- Renata Medical, a privately held medical technology company dedicated to transforming care for children with congenital heart disease (CHD), today announced the close of a $25 million Series D financing round. The round was led by ARCHIMED, a global investment firm focused exclusively on
More news about: Renata Medical
Aug 12, 2026, 09:01 ET Propel Bio Partners Highlights Progress of EIT Pharma Under Leadership of CEO Dr. Leen Kawas
Dr. Leen Kawas, EIT Pharma is advancing Lonafarnib, its late-stage investigational first-in-class oral therapy for chronic hepatitis D (CHD), and Lambda, its Phase 2 investigational treatment for severe acute viral respiratory infections. FDA recently accepted Lonafarnib's New Drug Application
More news about: Propel Bio Partners
Aug 11, 2026, 09:00 ET EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
Chronic hepatitis D (CHD) is a serious, life-threatening liver disease caused by hepatitis D virus (HDV) in individuals who already have hepatitis B virus infection. CHD can progress rapidly to cirrhosis, liver failure, liver cancer, and death. Despite
More news about: EIT Pharma
Jul 31, 2026, 12:20 ET KLADNÉ STANOVISKO CHMP PODPORUJE ŠIRŠÍ POUŽITÍ PŘÍPRAVKU REPATHA® SPOLEČNOSTI AMGEN PŘED PRVNÍM INFARKTEM NEBO MOZKOVOU MRTVICÍ
v listopadu 2025. Přípravek Repatha prokázal 25% relativní snížení rizika kombinovaného ukazatele zahrnujícího úmrtí na ischemickou chorobu srdeční (CHD), infarkt myokardu nebo ischemickou cévní mozkovou příhody (3-P MACE) a 19% snížení v širším kombinovaném ukazateli, který zahrnoval také jakoukoli revaskularizaci
More news about: Amgen
Jul 31, 2026, 10:00 ET Cincinnati Children's Receives $38.4 Million NIH Grant Renewal to Expand Landmark Congenital Heart Disease Genomics Program
more than 15 years of federal investment in the Congenital Heart Disease GEnetic NEtwork Study, or CHD GENES, which has enrolled more than 14,000 people with CHD and more than 18,000 family members.The grant runs from May 15, 2026, through April 30, 2032. It represents the
More news about: Cincinnati Children's Hospital Medical Center
Jul 29, 2026, 09:00 ET POSITIVE CHMP OPINION SUPPORTS BROADER USE OF AMGEN'S REPATHA® BEFORE A FIRST HEART ATTACK OR STROKE
England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization
More news about: Amgen
Jul 15, 2026, 17:47 ET /C O R R E C T I O N -- Cincinnati Children's Hospital Medical Center/
moments of diagnosis."Thriving with CHD vs survivingThis research is needed because care for babies with CHD has improved greatly. Thanks to better surgical and intensive care technologies, many newborns who once were not expected to survive CHD are getting opportunities to begin growing
More news about: Cincinnati Children's Hospital Medical Center
Jul 14, 2026, 12:57 ET Buchanan Capital Partners Forms Second Joint Venture with the Industrial Team at Crow Holdings Development
DevelopmentCrow Holdings Development (CHD) is a leading real estate development company specializing in multifamily, industrial, and office development across high-opportunity markets in the United States. Led by a highly experienced leadership team, CHD has developed nearly 300,000 multifamily units
More news about: Buchanan Capital Partners
Jun 29, 2026, 07:38 ET PAN GLOBAL COMMENCES PHASE 2 DRILLING AT CAÑADA HONDA DEPOSIT: PROVIDES ESCACENA PROJECT UPDATE, SPAIN
20.0 m grading 0.5% Cu and 0.8 g/t Au, including 5.1 m grading 1.3% Cu and 0.5 g/t Au (CHD05);20.0 m grading 1.1 g/t Au (CHD09); and5.6 m grading 1.15% Cu (CHD10).Subsequent drilling demonstrated continuity of mineralization from surface to at least 600
More news about: Pan Global Resources Inc.
Jun 29, 2026, 07:38 ET PAN GLOBAL COMMENCES PHASE 2 DRILLING AT CAÑADA HONDA DEPOSIT: PROVIDES ESCACENA PROJECT UPDATE, SPAIN
20.0 m grading 0.5% Cu and 0.8 g/t Au, including 5.1 m grading 1.3% Cu and 0.5 g/t Au (CHD05);20.0 m grading 1.1 g/t Au (CHD09); and5.6 m grading 1.15% Cu (CHD10).Subsequent drilling demonstrated continuity of mineralization from surface to at least 600
More news about: Pan Global Resources Inc.
Jun 29, 2026, 07:38 ET PAN GLOBAL BEGINNT MIT DEN BOHRARBEITEN DER PHASE 2 IN DER LAGERSTÄTTE CAÑADA HONDA: AKTUELLES ZUM ESCACENA-PROJEKT, SPANIEN
0,5 % Cu und 0,8 g/t Au, einschließlich 5,1 m mit einem Gehalt von 1,3 % Cu und 0,5 g/t Au (CHD05);20,0 m mit einem Gehalt von 1,1 g/t Au (CHD09); und5,6 m mit einem Kupfergehalt von 1,15 % (CHD10).Nachfolgende Bohrungen belegten die Kontinuität der Mineralisierung von der
More news about: Pan Global Resources Inc.
Jun 29, 2026, 07:38 ET PAN GLOBAL LANCE LA PHASE 2 DES FORAGES DANS LE GISEMENT DE CAÑADA HONDA : MISE À JOUR SUR LE PROJET ESCACENA, EN ESPAGNE
20,0 m titrant 0,5 % de Cu et 0,8 g/t d'Au, dont 5,1 m titrant 1,3 % de Cu et 0,5 g/t d'Au (CHD05) ;20,0 m titrant 1,1 g/t Au (CHD09) ; et5,6 m titrant 1,15 % de cuivre (CHD10).Les forages ultérieurs ont mis en évidence la continuité de la minéralisation depuis la
More news about: Pan Global Resources Inc.
Jun 29, 2026, 07:38 ET PAN GLOBAL INICIA LA FASE 2 DE SONDEOS EN CAÑADA HONDA Y ACTUALIZA LA INFORMACIÓN SOBRE EL PROYECTO ESCACENA
ley de 0,5 % de Cu y 0,8 g/t de Au, incluyendo 5,1 m con una ley de 1,3 % de Cu y 0,5 g/t de Au (CHD05);20,0 m con una ley de 1,1 g/t de Au (CHD09); y5,6 m con una ley de 1,15 % de Cu (CHD10).Sondeos posteriores demostraron la continuidad de la mineralización
More news about: Pan Global Resources Inc.
Jun 19, 2026, 07:32 ET NCL's Nanha Sa Dil - Transforming Rural Child Heart Care in India
they could, but nobody could tell them exactly what was wrong. Like many families in rural India, they had never heard of Congenital Heart Disease (CHD), a condition that affects thousands of children every year. The possibility of travelling to a specialized hospital or paying for advanced treatment
More news about: Northern Coalfields Limited (NCL)
Jun 16, 2026, 09:11 ET 16 Million People, One Underserved Disease: The AI Imaging Push to Close the Congenital Heart Gap
https://www.ventripoint.com/news[2] World Heart Federation — World Heart Report 2026 (CHD ~2% of live births; ~16 million people living with CHD, up from 11.8 million; >90% of children in LMICs lack timely CHD care):
More news about: Equity Insider
Jun 16, 2026, 09:04 ET Dr. Leen Kawas, CEO of EIT Pharma, Highlights on EASL Congress 2026
June 16, 2026 /PRNewswire/ -- EIT Pharma, Inc. presented new analyses from its lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. The presentations come under the leadership of Chief Executive Officer Dr. Leen Kawas,
More news about: EIT Pharma
Jun 07, 2026, 16:45 ET AMGEN PRESENTS NEW DATA ACROSS ITS CARDIOMETABOLIC PORTFOLIO AT AMERICAN DIABETES ASSOCIATION 86TH SCIENTIFIC SESSIONS
England Journal of Medicine in November 2025. Repatha demonstrated a 25% relative reduction in the risk of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke (3-P MACE), and 19% reduction in a broader composite that also included any ischemia-driven arterial revascularization
More news about: Amgen
Jun 06, 2026, 07:07 ET Program Open Day "Light Up the Future" China Huadian Perkuat Hubungan dan Kolaborasi Tiongkok-Indonesia
energi Indonesia, CHD selalu berpegang pada prinsip dialog, kontribusi bersama, dan manfaat kolektif. Selain ikut menjaga keandalan pasokan listrik regional, CHD juga terus menjalankan berbagai program pemberdayaan masyarakat dan kegiatan sosial. Melalui berbagai langkah nyata tersebut, CHD berkontribusi
More news about: China Huadian Corporation Ltd
Jun 01, 2026, 08:30 ET EIT Pharma Highlights New Lonafarnib Analyses at EASL Congress 2026
Pharma presented new analyses from the lonafarnib development program for Chronic Hepatitis Delta (CHD) at EASL Congress 2026 in Barcelona, Spain, held May 27–30, 2026. Due to the high unmet medical need in CHD, EIT Pharma resurrected the development of lonafarnib as the only late-stage oral option in late-stage
More news about: EIT Pharma
May 19, 2026, 08:55 ET Cardiac AI Diagnostics Stack Validation Wins Across Regulatory and Commercial Fronts
cardiac function over time in congenital heart disease (CHD) patients. The clinical rationale, as the Company described it, sits inside the 2020 ESC Guidelines for Adult Congenital Heart Disease — guidelines co-endorsed by AEPC — which identify CHD as a lifelong chronic condition requiring structured,
More news about: USA News Group
Apr 15, 2026, 10:30 ET Nicklaus Children's Hospital's Heart Institute Performs Florida's First Partial Heart Transplant
surgery."Congenital heart defects are the most common birth defects, affecting nearly 1% of newborns in the U.S., or about 40,000 infants. Of those infants born with CHD, half will need an operation to fix or replace a valve.Dr. Kalfa's work is supported in part by grants from the National Institutes of Health
More news about: Nicklaus Children's Hospital
Mar 31, 2026, 08:35 ET Standardizing Sustainability: ChinaAMC Leads the Way in Public REITs ESG disclosure
REIT, ChinaAMC CR Commercial REIT, ChinaAMC Joy City Commercial REIT, ChinaAMC CapitaLand Commercial REIT, ChinaAMC TBEA New Energy REIT, and ChinaAMC CHD Clean Energy REIT. Together, they form a diversified, full-spectrum matrix.Largest REITs fund manager. Pioneer in presenting ESG reportsChinaAMC
More news about: ChinaAMC
Mar 28, 2026, 16:45 ET REPATHA® CUTS RISK OF FIRST MAJOR CARDIOVASCULAR EVENTS BY 31% IN HIGH-RISK PATIENTS WITHOUT KNOWN SIGNIFICANT ATHEROSCLEROSIS
years from the Phase 3 VESALIUS-CV clinical trial. Results showed Repatha reduced the risk of the composite primary endpoint of coronary heart disease (CHD) death, myocardial infarction or ischemic stroke (3‑P MACE) by 31% compared with placebo. Repatha also reduced the risk of a dual composite primary endpoint
More news about: Amgen